Waldencast Gains FDA Nod for Obagi saypha ChIQ Filler for Cheek Augmentation
WALD•Waldencast received FDA approval for Obagi saypha ChIQ, a hyaluronic acid gel indicated for cheek augmentation and midface contour correction in adults over 21. This expands Obagi Medical’s injectable portfolio following strong feedback on saypha MagIQ, where 94% of injectors reported complementarity and 42.6% of practices began evaluating Obagi skincare.
1. FDA Approval and Indication
Waldencast announced FDA clearance of Obagi saypha ChIQ, an injectable hyaluronic acid gel indicated for cheek augmentation and correction of midface contour deficiencies in patients over 21. This approval marks the third addition to the Obagi Medical injectable line and positions the brand for deeper penetration in the fast-growing U.S. dermal filler segment.
2. Advanced MACRO Core Technology
Developed by Croma-Pharma, saypha ChIQ leverages proprietary MACRO Core Technology to deliver high usable HA content, consistent particle distribution, and predictable injection force and swelling profiles. These features aim to provide natural-looking, long-lasting outcomes and differentiate Obagi’s offering in a competitive aesthetic market.
3. Provider Feedback on saypha MagIQ
Earlier in 2026, Obagi saypha MagIQ garnered strong industry reception, with 94% of injectors noting it complements existing filler options. Practices using MagIQ reported a 42.6% rate of evaluating Obagi skincare in conjunction with fillers—over four times the industry norm of one in ten filler visits—highlighting cross-sell potential.
